SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.
Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.
Learn moreLatest news
21 Jun 2017
Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma
Data Presentations at European Hematology Association (EHA) 22nd Annual Congress Further Validate SkylineDx Prognostic Tools in Multiple Myeloma Posters Reinforce Value of MMprofiler™ Gene-based Prognostic Signature for: ...
Upcoming Events
19 Jun 2017 - 22 Jun 2017, San Diego, CA USA
BIO International Convention
22 Jun 2017 - 25 Jun 2017, Madrid, Spain
European Hematology Association - 22nd Congress
13 Sep 2017 - 16 Sep 2017, Houston, TX, USA
Society of Hematologic Oncology - 2017 Annual Meeting